Stocks of companies specializing in biotech-research tools have been pummeled in recent weeks, but several of them appear to have been oversold and could make a comeback, analysts say.
“These companies have been unduly punished,” said Peter Lawson, a life sciences analyst for Mizuho Securities. “As a long-term hold, they’re definitely a buying opportunity.”
Shares of toolmakers, which market products ranging from chemical reagents to genomic sequencers, have been under pressure for months, plagued by concerns that ongoing consolidation in the pharmaceutical industry, a major client, will eventually eat into sales.
The stocks fell further in July as the U.S. debt-limit crisis began to heat up.
Since that time, investors have been haunted by the notion that lawmakers will move to slash the National Institutes of Health’s budget, a major funding source for university and hospital researchers. The so-called supercommittee in Congress charged with forming a long-term deficit reduction plan is being closely watched in the biotech... Read More
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites